Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Stenocare A/S (STENO.CO)
DKK0.99
-0.01 (-0.80%)
DK CPH Healthcare Medical - Pharmaceuticals
Address
Nyholmsvej 4 8930
Randers, DC, DK
Randers, DC, DK
CEO
Thomas Skovlund Schnegelsberg
Website
stenocare.dk
IPO
2020-05-18
ISIN DK0061078425
Description
Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD oil products. The company was incorporated in 2017 and is based in Randers, Denmark.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
DKK0.99
-0.01 (-0.80%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
134.3K
Beta
0.51
Float Shares
25.38M
Free Float %
58.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.76% | -3.04% | -0.45% | -17.41% | -34.41% | -25.17% | +161.12% | -84.93% | -92.60% | -96.86% | -96.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.99
Quality scores
Altman Z-Score
11.66
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+214.5% ★ Q1'26: +284.2% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+94.5% ★ Q1'26: +79.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-113.4% Q1'26: +2.9% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-25.8% Q1'26: -11.3% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%-17.0% Q1'26: -13.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+25.2% Q1'26: +12.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-1.14× Q1'26: 6.26× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
3.76M
est: 6.50M (-42.2%)
|
2.23M
est: 2.00M (+11.6%)
|
7.02M
est: 6.50M (+8.0%)
|
16.50M
16.50M – 16.50M
+153.8% YoY
|
22.50M
22.50M – 22.50M
+36.4% YoY
|
28.30M
28.30M – 28.30M
+25.8% YoY
|
| EBITDA |
-12.56M
est: -6.50M (-93.3%)
|
-24.20M
est: -1.70M (-1,324.1%)
|
-1.74M
est: -5.52M (+68.5%)
|
-14.02M
-14.02M – -14.02M
-153.8% YoY
|
-19.12M
-19.12M – -19.12M
-36.4% YoY
|
-24.04M
-24.04M – -24.04M
-25.8% YoY
|
| EBIT |
-15.95M
est: -6.50M (-145.3%)
|
-33.06M
est: -1.70M (-1,841.1%)
|
-1.81M
est: -5.54M (+67.3%)
|
-14.05M
-14.05M – -14.05M
-153.8% YoY
|
-19.16M
-19.16M – -19.16M
-36.4% YoY
|
-24.10M
-24.10M – -24.10M
-25.8% YoY
|
| Net Income |
-17.57M
|
-34.49M
|
-2.39M
|
—
— – —
|
—
— – —
|
4.32M
4.32M – 4.32M
|
| SGA |
9.76M
est: 52.90M (-81.5%)
|
5.76M
est: 4.51M (+27.5%)
|
—
est: 14.67M (-100.0%)
|
37.24M
37.24M – 37.24M
+153.8% YoY
|
50.79M
50.79M – 50.79M
+36.4% YoY
|
63.88M
63.88M – 63.88M
+25.8% YoY
|
| EPS |
-1.26
|
-1.00
|
-0.06
|
—
— – —
|
—
— – —
|
0.10
0.10 – 0.10
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
29.27M
OE per share TTM
0.73
Owner's Yield
60.50%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
449.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-452.9K
Shares Outstanding
43.20M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Bugge Johansen | Chief Financial Officer | — | male |
| Rolf Steno Petersen | Co-Founder, Chief Commercial Officer & Director | — | male |
| Thomas Skovlund Schnegelsberg | Chief Executive Officer, Co-Founder & Member of Executive Board | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STENO.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
